MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413986 | Name: Oseltamivir Free Base
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Oseltamivir Free Base is an acetamido cyclohexene that is a structural homolog of sialic acid and inhibits neuraminidase. Oseltamivir significantly reduced risk of symptomatic laboratory-confirmed influenza and influenza-like illness.

Chemical Structure

Oseltamivir Free Base
Oseltamivir Free Base
CAS#196618-13-0 (free base)

Theoretical Analysis

MedKoo Cat#: 413986

Name: Oseltamivir Free Base

CAS#: 196618-13-0 (free base)

Chemical Formula: C16H28N2O4

Exact Mass: 312.2049

Molecular Weight: 312.41

Elemental Analysis: C, 61.51; H, 9.03; N, 8.97; O, 20.48

Price and Availability

Size Price Availability Quantity
100mg USD 250.00 2 Weeks
250mg USD 485.00 2 Weeks
500mg USD 750.00 2 Weeks
1g USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
204255-11-8 (phosphate) 196618-13-0 (free base) 204255-09-4 (HCl)
Synonym
Oseltamivir Free Base; GS4104; GS-4104; GS 4104
IUPAC/Chemical Name
1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R,4R,5S)-
InChi Key
VSZGPKBBMSAYNT-RRFJBIMHSA-N
InChi Code
InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1
SMILES Code
O=C(C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1)OCC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Oseltamivir Free Base is an acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.
In vitro activity:
Human lumbar IVD (n = 8) tissues were isolated for annulus fibrosus (AF) and nucleus pulposus (NP) primary cell cultures, and human tibial and femoral cartilage tissues (n = 8) were isolated for primary chondrocyte cultures. In the oseltamivir-treated groups, cell proliferation decreased in both AF/NP cell and chondrocyte cultures obtained from IVD cartilage tissues. After Western blotting analysis, changes were observed in the protein expressions of HIF-1α, IL-1β, NF-κB, and the NLRP3 inflammasome in both AF/NP cells and chondrocytes. The results were statistically significant (p < 0.05). Reference: Eur Rev Med Pharmacol Sci. 2022 Jul;26(13):4816-4827. https://pubmed.ncbi.nlm.nih.gov/35856374/
In vivo activity:
Immunocompetent mice received intranasal instillation influenza A or PBS followed by orotracheal inoculation with Aspergillus fumigatus 4 days later. Oseltamivir treatment or placebo was started at day 0, day 2, or day 4. Early oseltamivir treatment prevented severe influenza pneumonia and mitigated the development of IPA and associated mortality. A time-dependent treatment effect was consistently observed with imaging, molecular, and pathological analyses. Reference: Virulence. 2021 Dec;12(1):2493-2508. https://pubmed.ncbi.nlm.nih.gov/34546839/

Preparing Stock Solutions

The following data is based on the product molecular weight 312.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Yilmaz I, Akalan H, Oznam K, Karaarslan N, Yasar Sirin D, Ozbek H. Does oseltamivir protect human chondrocyte and nucleus pulposus cells from degeneration by inhibiting senescence and proinflammation mediated by the NLRP3 inflammasome and NF-κB? Eur Rev Med Pharmacol Sci. 2022 Jul;26(13):4816-4827. doi: 10.26355/eurrev_202207_29207. PMID: 35856374. 2. de Oliveira JT, Santos AL, Gomes C, Barros R, Ribeiro C, Mendes N, de Matos AJ, Vasconcelos MH, Oliveira MJ, Reis CA, Gärtner F. Anti-influenza neuraminidase inhibitor oseltamivir phosphate induces canine mammary cancer cell aggressiveness. PLoS One. 2015 Apr 7;10(4):e0121590. doi: 10.1371/journal.pone.0121590. PMID: 25850034; PMCID: PMC4388625. 3. Seldeslachts L, Vanderbeke L, Fremau A, Reséndiz-Sharpe A, Jacobs C, Laeveren B, Ostyn T, Naesens L, Brock M, Van De Veerdonk FL, Humblet-Baron S, Verbeken E, Lagrou K, Wauters J, Vande Velde G. Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model. Virulence. 2021 Dec;12(1):2493-2508. doi: 10.1080/21505594.2021.1974327. PMID: 34546839; PMCID: PMC8923074. 4. Takahashi E, Sawabuchi T, Kimoto T, Sakai S, Kido H. Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 feeding enhances humoral immune responses, which are suppressed by the antiviral neuraminidase inhibitor oseltamivir in influenza A virus-infected mice. J Dairy Sci. 2019 Nov;102(11):9559-9569. doi: 10.3168/jds.2019-16268. Epub 2019 Sep 5. PMID: 31495632.
In vitro protocol:
1. Yilmaz I, Akalan H, Oznam K, Karaarslan N, Yasar Sirin D, Ozbek H. Does oseltamivir protect human chondrocyte and nucleus pulposus cells from degeneration by inhibiting senescence and proinflammation mediated by the NLRP3 inflammasome and NF-κB? Eur Rev Med Pharmacol Sci. 2022 Jul;26(13):4816-4827. doi: 10.26355/eurrev_202207_29207. PMID: 35856374. 2. de Oliveira JT, Santos AL, Gomes C, Barros R, Ribeiro C, Mendes N, de Matos AJ, Vasconcelos MH, Oliveira MJ, Reis CA, Gärtner F. Anti-influenza neuraminidase inhibitor oseltamivir phosphate induces canine mammary cancer cell aggressiveness. PLoS One. 2015 Apr 7;10(4):e0121590. doi: 10.1371/journal.pone.0121590. PMID: 25850034; PMCID: PMC4388625.
In vivo protocol:
1. Seldeslachts L, Vanderbeke L, Fremau A, Reséndiz-Sharpe A, Jacobs C, Laeveren B, Ostyn T, Naesens L, Brock M, Van De Veerdonk FL, Humblet-Baron S, Verbeken E, Lagrou K, Wauters J, Vande Velde G. Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model. Virulence. 2021 Dec;12(1):2493-2508. doi: 10.1080/21505594.2021.1974327. PMID: 34546839; PMCID: PMC8923074. 2. Takahashi E, Sawabuchi T, Kimoto T, Sakai S, Kido H. Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 feeding enhances humoral immune responses, which are suppressed by the antiviral neuraminidase inhibitor oseltamivir in influenza A virus-infected mice. J Dairy Sci. 2019 Nov;102(11):9559-9569. doi: 10.3168/jds.2019-16268. Epub 2019 Sep 5. PMID: 31495632.
1: Esposito S, Principi N. Oseltamivir for influenza infection in children: risks and benefits. Expert Rev Respir Med. 2016;10(1):79-87. doi: 10.1586/17476348.2016.1126182. Epub 2015 Dec 19. PMID: 26616633. 2: Tagarro A, Cruz-Cañete M, Otheo E, Launes C, Couceiro JA, Pérez C, Alfayate S; en nombre del Grupo de trabajo de Infecciones Respiratorias de la Sociedad Española de Infectología Pediátrica (SEIP); Miembros del Grupo de Trabajo de Infecciones Respiratorias de la SEIP que han participado en la revisión del manuscrito. Oseltamivir para el tratamiento de la gripe en niños y adolescentes [Oseltamivir for the treatment of influenza in children and adolescents]. An Pediatr (Barc). 2019 May;90(5):317.e1-317.e8. Spanish. doi: 10.1016/j.anpedi.2019.01.009. Epub 2019 Feb 21. PMID: 30797703. 3: Doshi P, Heneghan C, Jefferson T. Oseltamivir for influenza. Lancet. 2016 Jan 9;387(10014):124. doi: 10.1016/S0140-6736(15)01282-9. Epub 2016 Jan 8. PMID: 26841993. 4: Butler CC, van der Velden AW, Bongard E, Saville BR, Holmes J, Coenen S, Cook J, Francis NA, Lewis RJ, Godycki-Cwirko M, Llor C, Chlabicz S, Lionis C, Seifert B, Sundvall PD, Colliers A, Aabenhus R, Bjerrum L, Jonassen Harbin N, Lindbæk M, Glinz D, Bucher HC, Kovács B, Radzeviciene Jurgute R, Touboul Lundgren P, Little P, Murphy AW, De Sutter A, Openshaw P, de Jong MD, Connor JT, Matheeussen V, Ieven M, Goossens H, Verheij TJ. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet. 2020 Jan 4;395(10217):42-52. doi: 10.1016/S0140-6736(19)32982-4. Epub 2019 Dec 12. PMID: 31839279. 5: Ono H. [Hypothermic Action of Oseltamivir Not Dependent on Its Anti-influenza Virus Action]. Yakugaku Zasshi. 2019;139(5):767-781. Japanese. doi: 10.1248/yakushi.18-00191. PMID: 31061347. 6: Lee J, Park JH, Jwa H, Kim YH. Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis. Yonsei Med J. 2017 Jul;58(4):778-785. doi: 10.3349/ymj.2017.58.4.778. PMID: 28540991; PMCID: PMC5447109. 7: Yun YL, Gao SH, Wen Y, Wang ZP, Miao HJ, Chen WS. Bioequivalence of two oseltamivir formulations in healthy Chinese volunteers. Int J Clin Pharmacol Ther. 2017 Sep;55(9):761-768. doi: 10.5414/CP202926. PMID: 28737128. 8: Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, Pan J, Zheng J, Lu B, Guo L, Wang C, Cao B. Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection. J Infect Dis. 2020 Apr 27;221(10):1688-1698. doi: 10.1093/infdis/jiz656. PMID: 31822885. 9: Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clin Infect Dis. 2018 May 2;66(10):1492-1500. doi: 10.1093/cid/cix1040. PMID: 29186364. 10: Rech MA. Oseltamivir for All: Should It Become an Over-the-Counter Medication for Influenza Treatment? Pharmacotherapy. 2020 Mar;40(3):182-185. doi: 10.1002/phar.2370. Epub 2020 Feb 12. PMID: 32048321. 11: Willcox ML, Lavu D, Yousaf U, Dalton S, Roberts N, Plüddemann A. The effectiveness of interventions to reduce the transmission of acute respiratory infections in care homes: a systematic review. J Public Health (Oxf). 2024 Aug 13:fdae178. doi: 10.1093/pubmed/fdae178. Epub ahead of print. PMID: 39136085.

View History

NSC-82472

NSC-82472